Download the presentation here: PDF
Download the presentation here: PDF
Download the presentation here: PDF
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Adolor / Pfizer: Making Opioids More Tolerant<br />
39<br />
Pharmaprojects PharmaprojectsR&D R&D Pipeline Pipeline News News Feed Feed<br />
Adolor Adolorand and Pfizer Pfizer join join forces forces on on novel novel pain pain compounds<br />
compounds<br />
7 Dec Dec 2007 2007<br />
Pfizer Pfizer has has signed signed a deal deal with with Adolor Adolorsecuring securing exclusive exclusive worldwide worldwide rights rights to to two two novel novel<br />
compounds compounds for for pain. pain. The The deal deal grants grants Pfizer Pfizer access access to to Adolor's Adolor'sADL-5859 ADL-5859 and and ADL- ADL-<br />
5747, 5747, both both proprietary proprietary delta delta opioid opioidreceptor receptor agonists agonists with with potential potential application application<br />
in in a wide wide range range of of inflammatory, inflammatory, neuropathic neuropathic and and acute acute pain pain conditions. conditions.<br />
T<strong>here</strong> T<strong>here</strong> are are three three known known opioid opioidreceptors receptors --mu, mu, kappa kappa and and delta. delta. All All current current opioid opioid<br />
analgesics analgesics exert exert <strong>the</strong>ir <strong>the</strong>ir effect effect mainly mainly on on <strong>the</strong> <strong>the</strong> mu mu variant, variant, with with no no presently-approved<br />
presently-approved<br />
compounds compounds targeted targeted specifically specifically at at <strong>the</strong> <strong>the</strong> kappa kappa or or delta delta types. types. Preclinical Preclinical work work suggests suggests<br />
that that delta-specific delta-specific agonists agonists may may exhibit exhibit superior superior analgesic analgesic properties properties to to mu mu agonists agonists<br />
whilst whilst avoiding avoiding some some of of <strong>the</strong>ir <strong>the</strong>ir common common and and undesirable undesirable side-effects.<br />
side-effects.<br />
ADL-5859 ADL-5859 is is <strong>the</strong> <strong>the</strong> most most advanced advanced compound, compound, currently currently in in Phase Phase IIa IIatrials trials in in<br />
inflammatory inflammatory pain, pain, with with more more Phase Phase II II trials trials planned planned for for 2008. 2008. An An IND IND for for ADL-5747 ADL-5747 is is<br />
pending pending and and Adolor Adoloris is planning planning to to initiate initiate clinical clinical development development in in <strong>the</strong> <strong>the</strong> first first quarter quarter of of<br />
2008. 2008.<br />
© Defined Health, 2009<br />
Pain Insight Briefing
Change language